David A. Siegel Biotechnology

Two Sigma Advisers, LP

$46.1 Billion
Q2 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
WVE Wave Life Sciences Ltd.	$734M	$599,000 0.0% of portfolio	92,300	Q2 2025 Added 211.82%
FULC Fulcrum Therapeutics, Inc.	$340M	$564,000 0.0% of portfolio	82,100	Q2 2025 Reduced 70.45%
FATE Fate Therapeutics Inc	$91.2M	$552,000 0.0% of portfolio	493,100	Q2 2025 Reduced 37.34%
BMEA Biomea Fusion, Inc.	$48.3M	$534,000 0.0% of portfolio	296,800	Q2 2025 Reduced 39.55%
PLRX Pliant Therapeutics, Inc.	$81.8M	$528,000 0.0% of portfolio	455,200	Q2 2025 Added 33.02%
ALEC Alector, Inc.	$165M	$527,000 0.0% of portfolio	377,000	Q2 2025 Reduced 4.05%
YMAB Y M Abs Therapeutics, Inc.	$372M	$521,000 0.0% of portfolio	115,700	Q2 2025 Reduced 19.26%
PMVP Pmv Pharmaceuticals, Inc.	$64.8M	$514,000 0.0% of portfolio	485,700	Q2 2025 Reduced 3.94%
IMAB I Mab	$320M	$506,000 0.0% of portfolio	209,383	Q2 2025 Reduced 42.35%
ALT Altimmune, Inc.	$177M	$500,000 0.0% of portfolio	129,200	Q2 2025 Reduced 51.12%
ABOS Acumen Pharmaceuticals, Inc.	$51M	$494,000 0.0% of portfolio	426,300	Q2 2025 Reduced 8.07%
INCY Incyte Corp	$18.2B	$490,000 0.0% of portfolio	7,200	Q2 2025 Reduced 80.6%
BCYC Bicycle Therapeutics PLC	$214M	$487,000 0.0% of portfolio	70,200	Q2 2025 New
SVRA Savara Inc	$294M	$454,000 0.0% of portfolio	199,315	Q2 2025 Reduced 24.42%
AKBA Akebia Therapeutics, Inc.	$610M	$447,000 0.0% of portfolio	123,049	Q2 2025 Reduced 5.16%
EPIX Essa Pharma Inc.	$84.2M	$443,000 0.0% of portfolio	260,800	Q2 2025 Reduced 5.54%
HLVX Hille Vax, Inc.	$69.5M	$421,000 0.0% of portfolio	211,600	Q2 2025 Added 106.69%
VRTX Vertex Pharmaceuticals Inc	$99.5B	$400,000 0.0% of portfolio	900	Q2 2025 New
MREO Mereo Biopharma Group PLC	$207M	$391,000 0.0% of portfolio	144,600	Q2 2025 Added 393.52%
ELYM Eliem Therapeutics, Inc.	$109M	$390,000 0.0% of portfolio	94,900	Q2 2025 Reduced 16.75%
DNLI Denali Therapeutics Inc.	$1.77B	$386,000 0.0% of portfolio	27,600	Q2 2025 Reduced 21.81%
VTYX Ventyx Biosciences, Inc.	$149M	$368,000 0.0% of portfolio	172,400	Q2 2025 Reduced 12.28%
DSGN Design Therapeutics, Inc.	$278M	$365,000 0.0% of portfolio	108,500	Q2 2025 Reduced 26.04%
ACET Adicet Bio, Inc.	$25.6M	$345,000 0.0% of portfolio	566,039	Q2 2025 Reduced 9.12%
GLUE Monte Rosa Therapeutics, Inc.	$208M	$326,000 0.0% of portfolio	72,500	Q2 2025 New
TBPH Theravance Biopharma, Inc.	$796M	$320,000 0.0% of portfolio	29,100	Q2 2025 Added 17.81%
EYPT Eye Point Pharmaceuticals, Inc.	$366M	$312,000 0.0% of portfolio	33,200	Q2 2025 Added 10.3%
TCRX T Scan Therapeutics, Inc.	$31.6M	$310,000 0.0% of portfolio	214,400	Q2 2025 Added 337.55%
ALXO Alx Oncology Holdings Inc	$25.3M	$295,000 0.0% of portfolio	703,300	Q2 2025 Added 3.27%
CGEN Compugen LTD	$127M	$291,000 0.0% of portfolio	163,484	Q2 2025 Added 53.96%
PRQR Pro Qr Therapeutics N.V.	$136M	$286,000 0.0% of portfolio	140,300	Q2 2025 Added 130.0%
ANTX An2 Therapeutics, Inc.	$20.6M	$285,000 0.0% of portfolio	269,600	Q2 2025 Reduced 39.42%
MRSN Mersana Therapeutics, Inc.	$590M	$281,000 0.0% of portfolio	937,000	Q2 2025 Added 262.9%
SLN Silence Therapeutics PLC	$201M	$229,000 0.0% of portfolio	39,600	Q2 2025 Reduced 19.51%
KROS Keros Therapeutics, Inc.	$353M	$228,000 0.0% of portfolio	17,100	Q2 2025 Reduced 85.69%
ERAS Erasca, Inc.	$191M	$227,000 0.0% of portfolio	179,200	Q2 2025 Reduced 47.77%
ARQT Arcutis Biotherapeutics, Inc.	$887M	$220,000 0.0% of portfolio	15,700	Q2 2025 Reduced 77.82%
MDXG Mimedx Group, Inc.	$821M	$210,000 0.0% of portfolio	34,500	Q2 2025 Reduced 76.48%
GLPG Galapagos Nv	$2.09B	$209,000 0.0% of portfolio	7,500	Q2 2025 Reduced 82.76%
IPSC Century Therapeutics, Inc.	$30.6M	$205,000 0.0% of portfolio	367,100	Q2 2025 Added 377.37%
IKNA Ikena Oncology, Inc.	$50M	$193,000 0.0% of portfolio	144,100	Q2 2025 Reduced 4.82%
CADL Candel Therapeutics, Inc.	$183M	$184,000 0.0% of portfolio	36,485	Q2 2025 New
PRLD Prelude Therapeutics Inc	$30.6M	$182,000 0.0% of portfolio	225,000	Q2 2025 Reduced 13.59%
ITOS I Teos Therapeutics, Inc.	$359M	$179,000 0.0% of portfolio	18,000	Q2 2025 New
SANA Sana Biotechnology, Inc.	$592M	$176,000 0.0% of portfolio	64,570	Q2 2025 New
ETNB 89bio, Inc.	$420M	$157,000 0.0% of portfolio	16,000	Q2 2025 Reduced 35.48%
NKTX Nkarta, Inc.	$95.4M	$146,000 0.0% of portfolio	88,400	Q2 2025 Reduced 26.52%
NVAX Novavax Inc	$663M	$136,000 0.0% of portfolio	21,700	Q2 2025 Reduced 96.47%
ADPT Adaptive Biotechnologies Corp	$1.81B	$132,000 0.0% of portfolio	11,400	Q1 2025 Reduced 77.91%
PGEN Precigen, Inc.	$375M	$118,000 0.0% of portfolio	83,600	Q2 2025 Added 2.33%

Shares Options

David A. Siegel

David A. Siegel is the co-founder and CEO of Two Sigma Advisers, a successful investment firm that uses technology and data-driven approaches to investing. Siegel is known for his expertise in quantitative investing and his innovative approach to investing. He has generated strong returns for his clients over the long term.

Track David A. Siegel's portfolio

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account